Adicet Bio Inc

Adicet Bio, Inc. (NASDAQ: ACET) is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases.

Recent Business and Financial Updates

• Financial Overview: In Q3 2025 (ended September 30), Adicet Bio reported a net loss of USD 26.9 million, or USD 0.29 per share, compared with USD 30.5 million (USD 0.34 per share) in Q3 2024. Research & Development (R&D) expenditures declined to USD 22.9 million (from USD 26.3 million), while General & Administrative (G&A) expenses decreased to USD 5.1 million (from USD 6.9 million). Cash, cash equivalents and short-term investments stood at USD 103.1 million as of September 30, 2025, down from USD 176.3 million at December 31, 2024. The company subsequently raised net proceeds of USD 74.8 million in October via a registered direct offering, extending its cash runway into the second half of 2027.
• Clinical and Pipeline Milestones: Adicet announced preliminary positive data from its Phase 1 trial of the lead candidate ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE): all seven treated patients showed rapid and sustained reductions in SLEDAI-2K score and Physician’s Global Assessment (PGA), with improved renal function—including three complete renal responses and two partial responses—and evidence of immune-reset B-cell repertoire remodelling. No Grade 2 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) events were observed. Based on these results, the company plans to request a meeting with the U.S. Food and Drug Administration (FDA) in Q1 2026 to discuss pivotal trial design, with initiation targeted for Q2 2026.
• Therapeutic Expansion and Oncology Strategy: Beyond the autoimmune indication, Adicet advanced its next-generation gamma delta CAR T cell programme ADI-212 in metastatic castration-resistant prostate cancer (mCRPC). The company presented preclinical data at the Prostate Cancer Foundation retreat, highlighting enhancements including membrane-tethered IL-12 (mbIL-12) armoring and CRISPR/Cas9-mediated MED12 disruption to boost potency in solid tumours. A regulatory filing for ADI-212 is on track for submission in Q1 2026, with initial clinical data expected in H2 2026. Enrollment is also underway in ADI-001 Phase 1 cohorts for systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and ANCA-associated vasculitis (AAV), and for treatment-refractory rheumatoid arthritis (RA).
• Cash Runway and Capital Structure: The company’s liquidity position was bolstered by the October 2025 equity raise of USD 74.8 million net, which extends the projected cash runway into H2 2027—assuming operating plans remain consistent with disclosed expectations. While the cash base of USD 103.1 million at September end is modest relative to biotech development demands, the raise materially improves capital flexibility. Nevertheless, given ongoing R&D and early-stage trials, the company remains dependent on future financing or milestone-based inflows to avoid dilution risk.
• Risk Factors and Development Outlook: Adicet’s progress is encouraging but remains early and contingent on several key assumptions: (a) the positive Phase 1 ADI-001 data will translate into a successful pivotal trial; (b) regulatory filing and clearance timelines for ADI-212 are met; (c) further financing can be secured without excessive dilution; and (d) the broader competitive and regulatory environment for allogeneic gamma-delta CAR T therapies remains favourable. Any delay in enrollment, safety setbacks, or cash-flow constraints could significantly impact the business model. The company emphasises that the forward-looking statements are subject to risks, including failure to obtain regulatory approval or meet development timelines.

Technical Observation (on the daily chart):

• Price Trend and Moving Averages: ACET remains in a clear downtrend, trading at USD 0.59 and staying below its 21-day and 50-day moving averages, indicating firm selling pressure and a continued corrective phase after breaking below key intermediate levels.
• Momentum Indicators and Sentiment: The RSI near 30 suggests oversold conditions and strong bearish sentiment, but its steady decline signals persistent weakness, with no immediate signs of a momentum reversal or supportive volume emerging.
• Support, Resistance, and Market Outlook: With low volumes and limited buyer interest, ACET faces downside risk toward the USD 0.45 support level, while meaningful recovery would require reclaiming the USD 0.76–0.82 resistance zone; overall sentiment remains cautious and technically weak.

Adicet Bio, Inc. (ACET) continues to demonstrate meaningful strategic and clinical advancement despite its current technical weakness, supported by strengthening fundamentals, expanding therapeutic validation, and a materially extended cash runway. The company reported improving financial efficiency with narrower quarterly losses, reduced operating expenses, and a fortified balance sheet following a USD 74.8 million capital raise that extends liquidity into the second half of 2027. Clinically, ACET delivered highly encouraging Phase 1 results for its lead asset ADI-001 in lupus nephritis and systemic lupus erythematosus, showing consistent clinical responses, renal improvement, and a favourable safety profile—positioning the program for pivotal-stage progression in 2026. In parallel, pipeline expansion into oncology through ADI-212 and the broadening of ADI-001 into additional autoimmune indications signal a robust multi-asset development trajectory. While the share price remains under technical pressure, oversold momentum indicators at current levels coincide with substantive operational progress, creating a fundamentally supportive backdrop for long-term value accretion as ACET advances its differentiated gamma-delta CAR-T platform toward late-stage clinical development. 

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Speculative Buy’ rating has been given Adicet Bio, Inc. (NASDAQ: ACET) at the closing price of USD 0.59, as of November 17, 2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is November 17, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.